INTERLEUKIN-1 RECEPTOR ANTAGONIST AMELIORATES EXPERIMENTAL ANTIGLOMERULAR BASEMENT-MEMBRANE ANTIBODY-ASSOCIATED GLOMERULONEPHRITIS

The contribution of IL-1 to leukocyte infiltration in anti-glomerular basement membrane(GBM) antibody(Ab) glomerulonephritis (GN) was examin ed by the administration of a specific IL-l receptor antagonist (IL-1r a). Lewis rats received anti-GBM Ab or normal rabbit serum and were tr eated with either 0.9% saline or 6 mg IL-1ra over a 24-h time period. Plasma IL-1ra concentration was 2,6591 +/- 51 ng/ml 4 h after anti-GEM Ab and IL-1ra administration. PMN and monocyte/macrophage infiltratio n declined 39% (9.8 +/- 1.9 to 6.0 +/- 1.5 PMN/glomerulus, P < 0.001) and 29% (4.9 +/- 0.8 to 3.5 +/- 0.8 ED-1 cells/glomerulus, P = 0.002) with IL-1ra treatment at 4 h, respectively. Similarly, the number of g lomerular cells staining for lymphocyte function-associated molecule-l p (CD18) declined 39% from 16.7 +/- 1.9 to 10.7 +/- 1.6 cells/glomerul us at 4 h (P = 0.0001). This was associated with a decrease in glomeru lar intracellular adhesion molecule-1 expression. The mean glomerular intracellular adhesion molecule-1 score in anti-GBM Ab GN rats treated with IL-1ra was less than that of rats administered anti-GBM Ab and 0 .9% saline at 4 (2.0 +/- 0.2 vs 2.5 +/- 0.2, P < 0.05) and 24 (2.5 +/- 0.1 vs 3.1 +/- 0.2, P = 0.0001) h. These immunopathologic changes cor related with a 50% reduction in proteinuria from 147 +/- 34 to 75 +/- 25 mg/d (P < 0.002). Treatment with IL-1ra did not affect the steady s tate mRNA expression of either IL-1 beta or TNF alpha. An increase in the IL-1ra dose to 30 mg given within the initial 4 h provided no addi tional benefit. The decline in PMN and monocyte/macrophage infiltratio n of the glomerulus at 4 h was similar to that found in the initial st udy. Furthermore, the protective benefit of IL-1ra was abrogated by do ubling the dose of the anti-GBM Ab GN, despite administering high dose IL-1ra (30 mg). In these studies, detectable IL-1ra was found in the serum of untreated anti-GBM Ab GN controls. These data suggest a posit ive yet limited role for IL-1ra in the therapeutic intervention of ant i-GBM Ab GN.